Scott Clarke brings with him more than 20 years of experience in the biotechnology and pharmaceutical industry. He most recently served as CEO of Trishula Therapeutics. He was responsible for launching Trishula as a stand-alone company focused on developing Tizona Therapeutics’ lead program following its acquisition by Gilead Sciences. Previously, Scott served as Tizona’s Chief Executive Officer. Under his leadership, Tizona’s two lead programs advanced into the clinic and the company built out its preclinical portfolio. He continues to serve on the Board of Directors of Trishula. Prior to Tizona, Scott served as Global Head of Oncology Partnering and Head of Asia and Emerging Markets Partnering at Roche. In this role, he was responsible for licensing, clinical collaborations, and acquisitions in oncology, and for sourcing opportunities across all indications from Asia. Scott has also held multiple positions at BioMarin, including serving as the Senior Vice President of Product Development, responsible for advancing its portfolio of clinical and late preclinical product candidates through approval. Prior to this role, Scott was Vice President of Business Development and Scientific Licensing overseeing all preclinical and early clinical licensing and M&A. Scott earned a BS in Chemical Engineering from the University of California, Berkeley, an MSc in Biotechnology at Northwestern University, and an MBA from London Business School.
Sign up to view 9 direct reports
Get started